The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...

CARsgen’s allogeneic CD38 CAR-T therapy administers first dose in an investigator-initiated trial: Shanghai, China Tuesday, January 21, 2025, 18:00 Hrs [IST] CARsgen Therapeutic ...

CAR NK cells are following closely behind. Cytovia has designed CAR NK cells against three targets: EGFR, GPC3 and CD38. The EGFR candidate is a dual-targeted CAR designed to hit both wild-type ...

Murine lymphocytes (T cells, B cells and NK cells) as well as myeloid cells, (DCs, macrophages and neutrophils) will be isolated from spleen, bone-marrow, tumour, and tumour-draining lymph nodes of ...

Natural killer (NK) cells are the human body’s first line of defense against cancer and infections but tend to get knocked down by treatment with anti-CD38 antibodies. This is because NK cells ...

The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.

Its Product Pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia ...